Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Issue 12 (7th October 2013)

• Record Type: Journal Article
• Authors: Arenillas, Leonor; Mallo, Mar; Ramos, Fernando; Guinta, Kathryn; Barragán, Eva; Lumbreras, Eva; Larráyoz, María‐José; De, Raquel; Tormo, Mar; Abáigar, María; Pedro, Carme; Cervera, José; Such, Esperanza; José Calasanz, María; Díez‐Campelo, María; Sanz, Guillermo F.; Hernández, Jesús María; Luño, Elisa; Saumell, Sílvia; Maciejewski, Jaroslaw; Florensa, Lourdes; Solé, Francesc
• Is Part Of: Genes, chromosomes & cancer. Volume 52:Issue 12(2013:Dec.)
• Page Start: 1167
• Page End: 1177
• Publication Date: 2013-10-07
• Subjects: Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22112
• Languages: English
• ISSNs: 1045-2257

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Cytogenetic aberrations identified by metaphase cytogenetics (MC) have diagnostic, prognostic, and therapeutic implications in myelodysplastic syndromes (MDS). However, in some MDS patients MC study is unsuccesful. Single nucleotide polymorphism array (SNP‐A) based karyotyping could be helpful in these cases. We performed SNP‐A in 62 samples from bone marrow or peripheral blood of primary MDS with an unsuccessful MC study. SNP‐A analysis enabled the detection of aberrations in 31 (50%) patients. We used the copy number alteration information to apply the International Prognostic Scoring System (IPSS) and we observed differences in survival between the low/intermediate‐1 and intermediate‐2/high risk patients. We also saw differences in survival between very low/low/intermediate and the high/very high patients when we applied the revised IPSS (IPSS‐R). In conclusion, SNP‐A can be used successfully in PB samples and the identification of CNA by SNP‐A improve the diagnostic and prognostic evaluation of this group of MDS patients. © 2013 Wiley Periodicals, Inc.</p> </abstract>